255 related articles for article (PubMed ID: 31587780)
21. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
22. Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
Mir H; Alhussein M; Alrashidi S; Alzayer H; Alshatti A; Valettas N; Mukherjee SD; Nair V; Leong DP
Can J Cardiol; 2018 Aug; 34(8):1059-1068. PubMed ID: 29980467
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
24. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
25. [Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor].
Guo X; Wang H; Zhou J; Duan L; Li Y; Si X; Zhang L; Fang L; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):627-632. PubMed ID: 31650944
[TBL] [Abstract][Full Text] [Related]
26. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
Zheng PP; Li J; Kros JM
Med Res Rev; 2018 Jan; 38(1):325-376. PubMed ID: 28862319
[TBL] [Abstract][Full Text] [Related]
27. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Toxicities Associated with Cancer Immunotherapies.
Wang DY; Okoye GD; Neilan TG; Johnson DB; Moslehi JJ
Curr Cardiol Rep; 2017 Mar; 19(3):21. PubMed ID: 28220466
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
32. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.
Herrmann J
Nat Rev Cardiol; 2020 Aug; 17(8):474-502. PubMed ID: 32231332
[TBL] [Abstract][Full Text] [Related]
33. The nephrotoxicity of new immunotherapies.
Sury K; Perazella MA
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
[No Abstract] [Full Text] [Related]
34. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
[TBL] [Abstract][Full Text] [Related]
35. [Cardiovascular toxicities associated with immune checkpoint inhibitors].
Wang WX; Song ZZ; Zhang YP
Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):609-613. PubMed ID: 32842453
[TBL] [Abstract][Full Text] [Related]
36. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
Ala CK; Klein AL; Moslehi JJ
Curr Cardiol Rep; 2019 Nov; 21(12):156. PubMed ID: 31768769
[TBL] [Abstract][Full Text] [Related]
37. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
[TBL] [Abstract][Full Text] [Related]
40. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
